Galvanize Therapeutics

Galvanize Therapeutics

Galvanize Therapeutics was created and incubated by ATP (Apple Tree Partners), with Jonathan Waldstreicher serving as founder. The company designs pulsed electric field (PEF) technologies that target cells involved in disease processes, distinguishing itself from both drugs and thermal ablation devices. Doug Godshall joined as chairman and CEO; other leaders include Chief Medical Officer William S. Krimsky and Chief Commercial Officer Gabe McHugh. The firm's lead platform, Aliya Pulsed Electric Field (PEF) energy, engages the body's molecular machinery to eliminate cells via regulated cell death mechanisms. A study published in November 2025 reported that Aliya PEF ablation achieved local control of lung tumors in metastatic cancer patients and may induce an immune response (per the firm, November 2025). The platform received FDA clearance in May 2026 for an expanded generator, the Aliya EX (per the firm, May 2026). Galvanize also partners with doctors and healthcare systems to deliver therapies. Investor backing includes Intuitive Surgical, Gilmartin Capital, T. Rowe Price, Sofinnova Partners, Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, and Longaeva. Team size and total deployment are not publicly disclosed. The company maintains a board of directors including Seth Harrison of ATP, Antoine Papiernik of Sofinnova Partners, Zack Scott of Norwest Venture Partners, David Lewis of Gilmartin Capital, and Laura Francis of SI-BONE. Galvanize is headquartered in San Carlos, California, with no additional offices listed. The firm participates in medical conferences such as AABIP and CHEST to present clinical data. As a venture-backed medical-device company incubated by a single VC (ATP), Galvanize’s structure is more corporate than a family office; its impurity as a family-office target lies in its operational focus on product development and FDA regulatory milestones. The absence of disclosed AUM, wealth origin, or investment strategy means allocators evaluating it would treat it as an operating company rather than a capital deployment entity.